Krittika Tanyasaensook. 2007. Primary response and safety of 90Yttrium ibritumomab tiuxetan followed by combined chemotherapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone for diffuse large B-cell lymphoma. Field of Study Pharmacology, Chulalongkorn University;

Krittika Tanyasaensook. Primary response and safety of 90Yttrium ibritumomab tiuxetan followed by combined chemotherapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone for diffuse large B-cell lymphoma. . Bangkok:Chulalongkorn University, 2007.

Krittika Tanyasaensook. (2007) Primary response and safety of 90Yttrium ibritumomab tiuxetan followed by combined chemotherapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone for diffuse large B-cell lymphoma . Chulalongkorn University/Bangkok.